CRISPR stock offers bold investment potential and how strategic portfolio management can boost resilience and long-term ...

In addition, ARK invested in another biotech firm, INTELLIA THERAPEUTICS INC (NASDAQ:NTLA), buying 53,270 shares for a total of $607,278. This purchase continues a series of investments in Intellia ...

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Intellia Therapeutics gains big investor interest as CRISPR pipeline progress fuels optimism despite stock volatility.

This little company's scientific breakthrough opened up a whole new sliver of the drug market (although it's still leading ...

In fact, Vertex's challenges this year might have created a solid entry point for a company that can be an excellent growth ...

In the latest round of daily trades, Cathie Wood’s ARK ETFs have made significant adjustments to their portfolios on Tuesday, September 2, 2025. The trades include major purchases in the biotech ...

Biotech is entering a new growth cycle driven by AI and CRISPR innovation, but current ETF valuations are high and volatility ...

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) executed a series of trades on Wednesday, September 3, 2025, according ...

Investment risk is often defined in terms of volatility, but that framing is incomplete. Metrics like beta may identify stocks that have historically swung up or down more than the ...

Cathie Wood doubles down on biotech, trims Roku and DraftKings. Cathie Wood came out swinging after a long weekend, putting ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.